COMMUNIQUÉS West-GlobeNewswire

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer
03/09/2025
-- Company Relocates Corporate Headquarters to Boca Raton -- Boca Raton, Fla., Sept. 03, 2025 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc . (“LIXTE” or the “Company”) (Nasdaq: LIXT and LIXTW), a clinical-stage [...]
Sensei Biotherapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
03/09/2025
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients [...]
KALA BIO to Present at H.C. Wainwright 27th Annual Global Investment Conference
03/09/2025
ARLINGTON, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of innovative therapies for rare [...]
Solésence Announces Key Leadership Appointments to Drive Future Innovation and Growth
03/09/2025
Strategic transformation of Solésence continues with Kevin Cureton promoted to President and Chief Executive Officer; Laura Riffner named Chief Financial Officer; Jess Jankowski to serve as Board Advisor ROMEOVILLE, Ill [...]
Lyell Immunopharma Announces the Initiation of a Phase 3 Head-to-Head CAR T-Cell Therapy Clinical Trial in Aggressive Large B-Cell Lymphoma and Formation of Expert Steering Committee
03/09/2025
PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second [...]
Opus Genetics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
03/09/2025
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies for the [...]
WeightWatchers Advances International Growth With Strategic Leadership Appointment
03/09/2025
Alejandro Bethlen to Lead WeightWatchers’ Next Phase of International Growth and Innovation, Building on More Than 50 Years in Global Markets NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: [...]
Fangzhou Secures 2nd National Science Foundation Project Approval, Deepens AI-Driven Healthcare Research
03/09/2025
SHANGHAI, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a leader in AI-driven Internet healthcare solutions, announced that its technology team will collaborate on a National [...]
Legendary Scientist and Biotech Veteran Joins CancerVax as Strategic Advisor
03/09/2025
Dr. Gordon Ringold to advise on various strategies related to the development of the Company’s novel cancer treatment platform Lehi, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, September 3, 2025 – CancerVax, Inc. , [...]
Renovamen Advisors® Launches to Help Early-Stage Biotechs Translate Breakthroughs into Scalable, Investable Business Models
03/09/2025
Renovamen Advisors ® Launches to Help Early-Stage Biotechs Translate Breakthroughs into Scalable, Investable Business Models Guiding biotech teams from scientific breakthroughs to commercial inflection with investor- [...]
Allegro appoints life sciences veteran as Chief Operating Officer to advance osteoarthritis treatment
03/09/2025
Stephan Crokaert, formerly of NeoMedLight, Abbott, Adagio and Boston Scientific, brings more than 35 years of strategic and commercial experience in life sciences Allegro prepares to advance lead product hydrocelin into [...]
Best Kratom Brand Products For Energy and Pain: Happy Go Leafy Introduces New Kratom Collection in 2025
03/09/2025
Discover premium, lab-tested Kratom products designed to boost energy, relieve pain, and support overall wellness with Happy Go Leafy’s 2025 collection. Glendale, CA, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Happy Go Leafy [...]
Pharming Group to present at the H.C. Wainwright 27th Annual Global Investment Conference
03/09/2025
Leiden, the Netherlands, September 3, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the H.C. Wainwright 27 th Annual Global [...]
NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer
03/09/2025
NMD Pharma Expands Senior Leadership Team with the Appointment of Ana de Vera as Chief Medical Officer Seasoned clinical development leader brings deep expertise in neuromuscular disease research, drug development, and [...]
Valneva Reports Further Positive Phase 2 Safety and Immunogenicity Results for Lyme Disease Vaccine Candidate
03/09/2025
Strong immune response after third yearly booster dose in children and adults Significant anamnestic antibody response across all six serotypes No safety concerns observed in any age group by independent Data Monitoring [...]
Valneva annonce de nouvelles données positives d’innocuité et d’immunogénicité de Phase 2 pour le candidat vaccin contre la maladie de Lyme
03/09/2025
Forte réponse immunitaire chez les enfants et les adultes après la troisième vaccination annuelle de rappel Forte réponse anamnestique observée pour les six sérotypes Aucun problème de sécurité observé dans toutes les [...]
BioSig Technologies Supplements Clarification on Recent Schedule 14A Filing. Closing of Merger with Streamex Exchange Corporation Not Affected
03/09/2025
Proposal No. 1 (The Acquisition Proposal) to be adjourned pending final NASDAQ approval; Company operations, financings and closing of the merger transaction remain not impacted LOS ANGELES and VANCOUVER, British [...]
Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock
03/09/2025
RADNOR, Pa., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities [...]
Eisai Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease Under Fast Track Status
03/09/2025
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless [...]

Pages